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   INTRODUCTION 
Vitamin B12 is a common name for a group of cobalt-
containing biologically active substances that differ in 
the structure of the ligand coupled to cobalt atom and 
called cobalamins.1 The main cobalamins in humans are 
hydroxocobalamin, adenosyl cobalamin and 
methylcobalamin, of which the latter two are active 
forms of coenzyme.2 In vitamin B12 preparations, 
cyanocobalamin is most commonly used as the active 
substance, which differs from other cobalamins in 
greater stability in the external environment and higher 
bioavailability, and therefore, it is cyanocobalamin that 
is usually referred to as “vitamin B12” in clinical 
practice.3 Vitamin B12 is involved in numerous 
physiologic processes required for normal growth, 
development, and metabolism of humans, and its 
deficiency can lead to severe, including life-threatening, 
disorders of various organs and systems. Studies 
conducted in recent decades worldwide have shown an 
increase in the prevalence of vitamin B12 deficiency, 
including its subclinical form, which may be due to both 
improved diagnosis and ageing of population and 
associated polymorbidity. This is the reason for the 
ongoing search for new approaches to the diagnosis and 
treatment of B12-deficient states. 
 
Vitamin B12 enters the body with proteins of food from 
which it is released at low pH in the stomach lumen.4 
After release, it binds to haptocorrin and remains 
complexed with it until proteolytic cleavage in the 
duodenum, where it binds to the Castle’s intrinsic 
factor. After entering the brush border of the 




intrinsic factor and enters the bloodstream, where it 
binds to transcobalamin II or haptocorrin, which deliver 
cobalamin to peripheral tissues and the liver.4 Most of 
the cobalamin transported by haptocorrin is 
metabolically inactive. Castle’s intrinsic factor is 
responsible for absorption of approximately 99% of 
vitamin B12, while 0.5‒5% is absorbed from the mucosa 
by simple diffusion all along the gastrointestinal tract. 4-
5 Vitamin B12 is distributed to almost all organs and 
tissues. Its steady-state concentrations are produced 
most rapidly in plasma, red blood cells, liver and 
kidneys, more slowly in adipose tissue, skeletal muscles, 
bone and brain.6 The main site of vitamin B12 deposition 
is the liver, where up to 90% of its reserves are 
concentrated.6 Up to 3‒7 μg of vitamin B12 are excreted 
with bile from liver into the intestines per day, and 
about 75% of this amount is reabsorbed. Enterohepatic 
circulation determines the long half-life of vitamin B12 
from the liver, about 12 months.7 In the body, 
cyanocobalamin is converted to coenzyme forms, 
methylcobalamin and 5-deoxyadenosylcobalamin. 
Methylcobalamin is involved in numerous 
transmethylation reactions and acts as a coenzyme for 
methionine synthase catalyzing the conversion of 
homocysteine to methionine required for the formation 
of S-adenosyl methionine, a universal methyl group 
donor for almost 100 different substrates, including 
DNA, RNA, hormones, proteins, and lipids.3,4 
Methionine is required for the conversion of folic acid 
to folinic acid, which provides a normoblastic type of 
hematopoiesis. 5-deoxyadenosylcobalamin is a cofactor 
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in succinyl-CoA during the degradation of propionic 
acid, which plays an important role in the metabolism 
of carbohydrates and lipids.5 Cobalamin deficiency 
results in accumulation of methylmalonic acid and 
neurologic symptoms. Succinyl-CoA is also necessary 
for the synthesis of hemoglobin.5 Cells that divide 
rapidly need vitamin B12 most. Vitamin B12 deficiency 
leads to impaired proliferation of hematopoietic cells 
and epithelial cells, increased concentrations of 
propionic and methylmalonic acids that have a 
damaging effect on the myelin sheaths of nerve fibers, 
and Hcy, which is a risk factor for cardiovascular 
complications.8 Clinically, vitamin B12 deficiency can 
manifest as lesions of various organs and systems. The 
classic manifestation of B12 hypovitaminosis is 
considered pernicious (B12-deficient) anemia associated 
with insufficient production of the Castle’s intrinsic 
factor by parietal cells of the stomach.  
 
However, in recent years, neurological manifestations of 
vitamin B12 deficiency have become a priority, such as 
sensory and motor disorders, ataxia, cognitive 
impairment, including those leading to dementia and 
mental disorders, which often occur in the absence of 
hematological disorders.9 In epidemiological studies, 
vitamin B12 deficiency was associated with the 
occurrence of infertility, delayed development of 
children, as well as thrombosis, including thrombosis of 
cerebral venous sinuses.7,10 Thrombosis was observed in 
severe vitamin B12 deficiency, resulting in marked 
hyperhomocysteinemia.7 In the elderly, vitamin B12 
deficiency was also associated with decreased tolerance 
to orthostatic hypotension, being an important cause of 
falls and associated fractures11, with an increased risk of 
age-related macular degeneration12, senile asthenia13, 
and sarcopenia14, which are important causes of 
disability. Vitamin B12 deficiency may develop due to its 
insufficient intake with food, increased need, 
malabsorption, disturbance in transport or metabolism. 
Since vitamin B12 metabolism in the body is 
complicated, it can cause vitamin deficiency at any 
stage. The latter is especially typical for the elderly due 
to age-related physiological changes, polymorbidity and 
polypharmacy.2 In economically developed countries, 
the most common causes of vitamin B12 deficiency 
include atrophic gastritis, administration of medicinal 
products that reduce gastric acidity, metformin, and 
chloramphenicol.15 The elderly are at highest risk of 
developing vitamin B12 deficiency, especially those over 
75 years old.3 In economically developed countries, the 
prevalence of vitamin B12 deficiency is about 6% in 
people under 60 years of age, about 20% in those over 
60 years of age16, and 23‒37% in those over 80 years of 
age17, but its actual prevalence in the elderly may be 
even higher because symptoms of deficiency in the 
elderly may be masked by age-related changes and 
comorbidities.2 About 10‒25% of the elderly have 
subclinical vitamin B12 deficiency characterized by low 
serum levels of the vitamin in the complete absence of 
clinical symptoms or with mild general symptoms that 
are often mistakenly associated with other disorders.18 It 
should be noted that the development of clinical 
symptoms of vitamin B12 deficiency since the onset of 
etiological factor can be delayed by 3‒10 years due to its 
high body stores and long half life in the liver.12,18 
However, even subclinical vitamin B12 deficiency can 
lead to increased serum Hcy concentration and an 
increased risk of cardiovascular diseases19,20 and, 
apparently, cognitive impairment.21 The main 
development mechanism of vitamin B12 deficiency in 
the elderly, occurring in 40‒70% of cases, is the food-
cobalamin malabsorption syndrome, a disorder 
characterized by the inability to release cobalamin from 
the link with food proteins, which leads to the 
unavailability of the vitamin to form the complex with 
the Castle’s intrinsic factor.22,23 Factors contributing to 
this syndrome include atrophic gastritis, Helicobacter 
pylori infection, antisecretory drugs, alcohol abuse, 
gastric bypass or certain other GI surgeries, and chronic 
exocrine pancreatic insufficiency.22 It should be kept in 
mind that absorption of vitamin B12 from food worsens 
as early as at the age of over 50 years.3 In addition, 
elderly people with normal serum vitamin B12 values 
may have its functional deficiency due to oxidative 
stress.23 The risk of both pernicious anemia and 
neuropsychiatric disorders is significantly higher in the 
elderly than that in younger people.9,24 Many elderly 
patients, especially those with comorbidity, such as 
renal insufficiency and/or diabetes mellitus, even with 
normal serum levels of cobalamin and HoloTC, may 
have elevated MMA levels, which led to the hypothesis 
that they are resistant to cobalamin and, consequently, 
should be prescribed higher doses of vitamin B12.25 
Other vulnerable population categories for vitamin B12 
deficiency include vegans and strict vegetarians, 
pregnant and breastfeeding women, infants of the first 
2 years of life, particularly those who were exclusively 
breastfed, those with pernicious anemia, celiac disease, 
and Crohn’s disease, those who underwent GI surgery 
resulting in the impaired production of the Castle’s 
intrinsic factor and hydrochloric acid secretion.10,25 The 
need for vitamin B12 is also increased in people who 
abuse alcohol, smokers, and those with HIV infection, 
tuberculosis, kidney disease, hyperthyroidism, and 
diabetes mellitus.10,25 Given the potentially serious 
consequences of vitamin B12 deficiency and the 
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irreversibility of some of them, in particular 
neurological ones in case of delayed initiation of 
treatment26, it is necessary to identify the deficiency in 
early stages and to prescribe treatment in a timely 
manner.27 Therefore, screening for vitamin B12 
deficiency in populations with risk factors is advisable. 
According to experts, screening for vitamin B12 
deficiency may be warranted in patients with one or 
more risk factors, such as gastric or small intestine 
resection, inflammatory bowel disease, administration 
of metformin for more than 4 months, administration of 
proton pump inhibitors or H2 blockers for more than 12 
months, veganism or strict vegetarianism, and age over 
75 years.3 Since the risk of serious consequences of 
vitamin B12 deficiency, including pernicious anemia, 
cognitive and behavioral disorders, depression, 
myocardial infarction, stroke is highest in the elderly, 
many researchers advise screening for vitamin B12 
deficiency in all the elderly.22 It is possible that in 
addition to the elimination of neurological and 
hematological symptoms, vitamin B12 may have other 
favorable effects in the elderly, such as antidepressant, 
antipsychotic22, analgesic, and opioid-sparing.28 As of 
now, there is no gold standard for diagnosing vitamin 
B12 deficiency. Furthermore, there is no commonly 
accepted determination of normal vitamin B12 levels. 
The World Health Organization considers the vitamin 
B12 status in adults to be sufficient at serum levels 
greater than 221 pmol/L. Levels of 148 to 221 pmol/L are 
considered low, and less than 148 pmol/L are considered 
B12 deficiency.29 Several circulating biomarkers can be 
identified for diagnostic purposes: total B12, active B12 
(HoloTC), and 2 metabolic markers, Hcy and MMA. The 
determination of each of these biomarkers has its 
limitations, as their level may be altered by some 
nonspecific factors, therefore taking into account the 
availability and cost of tests, a stratified stepwise 
approach, starting with the determination of total 
vitamin B12 level and complete blood count are typically 
advised to assess B12 deficiency.27 
 
Patients with serum cobalamin levels IN the range of 
110‒148 pmol/L are recommended to be retested in 1‒2 
months.30 Patients with persistent suboptimal 
cobalamin levels should be tested for titers of Castle’s 
intrinsic factor antibodies and given low doses of oral 
vitamin B12. Such patients should be warned of the need 
to closely monitor for potential neurologic symptoms 
and if they occur, seek medical attention immediately. 
Patients with positive tests for the Castle’s intrinsic 
factor  antibodies   should   be   treated  according to the  
 
therapeutic guidelines for pernicious anemia. In 
patients with negative test results, the cobalamin levels 
should be re-evaluated in 3‒4 months and, if remained 
low, the biochemical testing should be continued to 
confirm biochemical deficiency.31 It is a paradox that 
some patients with symptoms of vitamin B12 deficiency 
have elevated serum cobalamin levels with parallel 
elevation of MMA and Hcy markers. This functional 
deficiency of cobalamin, which is more often 
asymptomatic, can develop with increased binding of 
vitamin B12 to haptocorrin rather than transcobalamin 
II, followed by a decrease in the vitamin delivery to 
peripheral cells.4 These patients are recommended to 
receive trial therapy with hydroxocobalamin.30 Elevated 
B12 levels are usually associated with liver disease and 
hematologic abnormalities, but may occur in some 
cancers4, suggesting that some cancers may impair the 
metabolism of vitamin B12. Repeated intramuscular 
injections of vitamin B12 have been considered the gold 
standard of therapy for B12-deficient states, but they 
have a number of limitations that can degrade quality of 
life. First, injections are painful, causing fear of 
treatment or refusal in a number of patients. Second, 
they cause adverse reactions at the injection site, 
including intramuscular hematomas, especially in 
individuals receiving concomitant antithrombotic 
therapy.2  
 
Injectable forms of vitamin B12 are more allergenic than 
tablets. In addition, injectable products require 
consumables and healthcare professionals for their 
administration, which in combination with an increased 
risk of adverse reactions and the high cost of injectable 
therapy, leads to an additional economic burden for 
patients themselves and the healthcare system. Given 
the fact that many patients, such as those with 
pernicious anemia or irreversible digestive tract 
disorders, require lifelong vitamin B12 replacement 
therapy, it can have significant negative medical and 
economic effects. An alternative to injectable products 
is the high-dose oral cyanocobalamin agents, which 
create sufficient cobalamin concentrations in the blood 
through diffuse absorption mechanism, including in 
patients with cobalamin malabsorption of various 
etiologies, including Castle’s intrinsic factor deficiency, 
atrophic gastritis, surgeries and antisecretory drugs. The 
efficacy and safety of oral drugs containing 1,000 μg of 
cyanocobalamin in individuals with vitamin B12 
deficiency have been demonstrated in numerous 
studies, including comparative ones with intramuscular 




 International Healthcare Research Journal 2021;5(4):RV1-RV5.  
Vitamin B12 Deficiency: Screening & Treatment                                                                                                                             Parul Sahni  
CONCLUSION 
Research work conducted in recent years across the 
globe indicates an increase in the prevalence of vitamin 
B12 deficiency. Further studies are required to detail the 
features of the pharmacokinetics and 
pharmacodynamics of vitamin B12, the causes and risk 
factors for the development and clinical manifestations 
of its deficiency. Also, the concerned professionals 
should provide updated modern recommendations for 
screening and diagnosis of vitamin B12 deficiency.  
 
REFERENCES 
1. Kennedy DO. B vitamins and the brain: Mechanisms, 
dose and efficacy —A review. Nutrients. 2016;8:68. 
https://doi.org/10.3390/nu8020068. 
2. Andrès E, Zulfiqar AA, Vogel T. State of the art review: 
oral and nasal vitamin B12 therapy in the elderly. QJM. 
2020;113(1):5-15. https://doi.org/10.1093/qjmed/hcz046 
3. Langan RC, Goodbred AJ. Vitamin B12 Deficiency: 
Recognition and Management. Am Fam Physician. 
2017;96(6):384-9. 
4. Shipton MJ, Thachil J. Vitamin B12 deficiency — A 21st 
century perspective. Clin Med (Lond). 2015;15(2):145-50. 
https://doi.org/10.7861/clinmedicine.15-2-14 
5. Romain M, Sviri S, Linton DM, Stav I, van Heerden 
PV. The role of Vitamin B12 in the critically ill — a 
review. Anaesth Intensive Care. 2016; 44(4):447-52. 
6. Alpers DH. Absorption and blood/cellular transport 
of folate and cobalamin: Pharmacokinetic and 
physiological considerations. Biochimie. 2016; 126:52-6. 
https://doi.org/10.1016/j.biochi.2015.11 
7. Stabler SP. Clinical practice. Vitamin B12 deficiency. 
N Engl J Med. 2013;368(2):149-
160.https://doi.org/10.1056/NEJMcp1113996 
8. Carmel R. Current concepts in cobalamin deficiency. 
Annu Rev Med. 2000; 51:357-375. 
https://doi.org/10.1146/annurev.med.51.1.357 
9. Andrès E, Loukili NH, Noel E, Kaltenbach G, 
Abdelgheni MB, Perrin AE, Noblet-Dick M, Maloisel F, 
Schlienger JL, Blicklé JF. Vitamin B12 (cobalamin) 
deficiency in elderly patients. CMAJ. 2004;171(3):251-259. 
https://doi.org/10.1503/cmaj.1031155 
10. Sukumar N, Saravanan P. Investigating vitamin B12 
deficiency. BMJ. 2019; 365:11865. 
https://doi.org/10.1136/bmj.l1865 
11. Moore A, Ryan J, Watts M, Pillay I, Clinch D, Lyons 
D. Orthostatic tolerance in older patients with vitamin 
B12 deficiency before and after vitamin B12 replacement. 
Clin Auton Res. 2004;14(2):67-71. 
https://doi.org/10.1007/s10286-004-0142-x 
12. Gopinath B, Flood VM, Rochtchina E, Wang JJ, 
Mitchell P. Homocysteine, folate, vitamin B-12, and 10-y  
 
incidence of age-related macular degeneration. Am J 
Clin Nutr. 2013;98(1):129-135. 
https://doi.org/10.3945/ajcn.112.057091 
13. Soh Y, Won CW. Association between frailty and 
vitamin B12 in the older Korean population. Medicine 
(Baltimore). 2020;99(43):e22327. 
https://doi.org/10.1097/MD.0000000000022327 
14. Ates Bulut E, Soysal P, Aydin AE, Dokuzlar O, 
Kocyigit SE, Isik AT. Vitamin B12 deficiency might be 
related to sarcopenia in older adults. Exp Gerontol. 
2017;95:136-40. 
https://doi.org/10.1016/j.exger.2017.05.017 
15. Green R, Allen LH, Bjørke-Monsen AL, Brito A, 
Guéant JL, Miller JW, Molloy AM, Nexo E, Stabler S, Toh 
BH, Ueland PM, Yajnik C. Vitamin B12 deficiency. Nat 
Rev Dis Primers. 2017;3:17040. 
https://doi.org/10.1038/nrdp.2017.40 
16. Hunt A, Harrington D, Robinson S. Vitamin B12 
deficiency. BMJ. 2014; 349:g5226. 
https://doi.org/10.1136/bmj.g5226 
17. Johnson MA, Hausman DB, Davey A, Poon LW, Allen 
RH, Stabler SP; Georgia Centenarian Study. Vitamin B12 
deficiency in African American and white octogenarians 
and centenarians in Georgia. J Nutr Health Aging. 
2010;14(5):339-45. https://doi.org/10.1007/s12603-010-
0077-y 
18. Carmel R. How I treat cobalamin (vitamin B12) 
deficiency. Blood. 2008; 112(6):2214-21. 
https://doi.org/10.1182/blood-2008-03-040253 
19. Ammouri W, Tazi ZM, Harmouche H, Maamar M, 
Adnaoui M. Venous thromboembolism and 
hyperhomocysteinemia as first manifestation of 
pernicious anemia: a case series. J Med Case Rep. 
2017;11(1):250. https://doi.org/10.1186/s13256-017-1415-z 
20. Kim J, Kim H1, Roh H, Kwon Y. Causes of 
hyperhomocysteinemia and its pathological 
significance. Arch Pharm Res. 2018;41(4):372-83. 
https://doi.org/10.1007/s12272-018-1016-4 
21. Carmel R. Subclinical cobalamin deficiency. Curr 
Opin Gastroenterol. 2012; 28(2):151-8. 
https://doi.org/10.1097/MOG.0b013e3283505852 
22. Wong CW. Vitamin B12 deficiency in the elderly: is 
it worth screening? Hong Kong Med J. 2015;21(2):155-164. 
https://doi.org/10.12809/hkmj144383 
23. Solomon LR. Functional cobalamin (vitamin B12) 
deficiency: role of advanced age and disorders 
associated with increased oxidative stress. Eur J Clin 
Nutr. 2015;69:687-92. 
https://doi.org/10.1038/ejcn.2014.272 
24. Zik C. Late Life Vitamin B12 Deficiency. Clin Geriatr 




 International Healthcare Research Journal 2021;5(4):RV1-RV5.  
Vitamin B12 Deficiency: Screening & Treatment                                                                                                                             Parul Sahni  
https://doi.org/10.1016/j.cger.2019.03.004 
25. Solomon LR. Disorders of cobalamin (vitamin B12) 
metabolism: emerging concepts in  pathophysiology, 
diagnosis and treatment. Blood Rev. 2007;21(3):113-30. 
https://doi.org/10.1016/j.blre.2006.05.001 
26. Briani C, Dalla Torre C, Citton V, Manara R, 
Pompanin S, Binotto G, Adami F. Cobalamin deficiency: 
clinical picture and radiological findings. Nutrients. 
2013;5(11):4521-39. https://doi.org/10.3390/nu5114521 
27. Jarquin Campos A, Risch L, Nydegger U, Wiesner J, 
Vazquez Van Dyck M, Renz H, Stanga Z, Risch M. 
Diagnostic Accuracy of Holotranscobalamin, Vitamin 
B12, Methylmalonic Acid, and Homocysteine in 
Detecting B12 Deficiency in a Large, Mixed Patient 
Population. Dis Markers. 2020;2020: 7468506. 
https://doi.org/10.1155/2020/7468506 
28. Buesing S, Costa M, Schilling JM, Moeller-Bertram T. 
Vitamin B12 as a Treatment for Pain. Pain Physician. 
2019;22(1):45-52. 
29. Hannibal L, Lysne V, Bjørke-Monsen AL, Behringer 
S, Grünert SC, Spiekerkoetter U, Jacobsen DW, Blom HJ. 
Biomarkers and Algorithms for the Diagnosis of Vitamin 
B12 Deficiency. Front Mol Biosci. 2016;3:27. 
https://doi.org/10.3389/fmolb.2016.00027 
30. Devalia V, Hamilton MS, Molloy AM; British 
Committee for Standards in Haematology. Guidelines 
for the diagnosis and treatment of cobalamin and folate 
disorders. Br J Haematol. 2014;166(4):496-513. 
https://doi.org/10.1111/bjh.12959 
31. Arendt JFH, Sørensen HT, Horsfall LJ, Petersen I. 
Elevated Vitamin B12 Levels and Cancer Risk in UK 
Primary Care: A THIN Database Cohort Study. Cancer 


















AUTHOR AFFILIATIONS: (*Corresponding Author) 
1. BDS, Pharmacovigilance Expert, Haryana, India 
 
Source of support: Nil, Conflict of interest: None declared 
Cite this article as: 
Sahni P. The Screening and Treatment of Vitamin B12 Deficiency.  Int Healthc Res J. 
2021;5(4):RV1-RV5. https://doi.org/10.26440/IHRJ/0504.07439 
Correspondence Address: 
Dr. Parul Sahni  
#884/12A Panchkula, Haryana, India 
RV5 
